Burden of Desmoid tumors
4 evidence topics · 35 sources
Summary: definition, etiology, incidence, and prevalence
- Desmoid tumor is a “rare and locally aggressive monoclonal, fibroblastic proliferation” with infiltrative growth, a tendency toward local recurrence, and an inability to metastasize. Of desmoid tumors, 85-90% are sporadic, and 85% of these result from somatic CTNNB1 mutations (Immunome Form 10-K); CTNNB1 mutations were observed in 117 of 138 tumors (85%) in one series, and one CTNNB1 alteration was found in 435 cases (84.3%) in the ALTITUDES cohort.
- Approximately 5–10% of desmoid tumors arise with familial adenomatous polyposis (FAP), and 39 of 519 participants (7.5%) in a Dutch nationwide pathology registry had FAP. Among patients with FAP, 36 of 328 (11.0%) in a U.S. community-based cohort and 66 of 735 (9%) in another cohort developed desmoid tumors; a family history of desmoids (30% vs 6.7%) and colorectal surgery were associated with higher risk. Antecedent trauma was verified in 164 participants (32.7%) in one series, including prior surgery in 98, and pregnancy and estrogen are listed as risk factors.
- Incidence estimates come from European studies: an increase from 2.10 to 5.36 per million people per year for extra-abdominal and abdominal wall tumors in the Netherlands (1993 to 2013); 3.42 per million person-years for sporadic tumors in the Netherlands (1999 to 2009); an average of 3.2 per 1,000,000 individuals per year in Denmark (2009 to 2018); 2.4–4.3 per million in Finland; and 5–6 cases per 1 million per year in the Desmoid Tumor Working Group guideline. A literature review estimated 3–5 cases per million person-years and identified no epidemiological study in the United States and no prevalence study.
- Most cases appear between ages 20 and 44, with 2.2–3.9 female cases for each male case; in Denmark, 76% of 179 participants were female and the median age at diagnosis was 38 years.
- Most U.S. figures are company estimates. SpringWorks Therapeutics (Form 10-K) estimates 1,000 to 1,650 new diagnoses each year, approximately 5,500 to 7,000 actively managed patients in any given year over the next decade (from market research with feedback from over 400 physicians), and approximately 11,000 patients receiving physician care annually (from ICD-10 claims between October 2023 and October 2024). Immunome states 1,000-1,650 patients diagnosed each year and 10-11,000 actively managed patients in the U.S., citing Bektas et al. and an “Immunome Analysis”. A published estimate gives an annual U.S. incidence of 1000 patients.
- In Germany, the G-BA took into account the company dossier's figure of approximately 350 to 630 adults with progressing desmoid tumours requiring systemic treatment and described these numbers as subject to uncertainty.
Summary: natural history, recurrence, and mortality
- Without treatment, an estimated 10–28% of desmoid tumors resolve spontaneously, 30% cycle through progression and resolution, 50% remain stable, and 10% progress rapidly.
- In a pooled analysis of three prospective observational studies of active surveillance (282 participants, median follow-up 53 months), 5-year treatment-free survival was 66%, and the 5-year crude cumulative incidences were 34% for RECIST progression and 34% for RECIST regression. In a United Kingdom cohort of 168 participants initially managed with active surveillance, 46% proceeded to treatment, after a median of 31 months.
- In the ALTITUDES nationwide prospective cohort (628 participants enrolled), the estimated 3-year event-free survival was 66.2%. In a prospective study of 771 cases, 2-year event-free survival was 53% after surgery and 58% with the wait-and-see approach (p = 0.415).
- After complete gross resection, 100 of 439 participants (23%) had recurrence, and 5-year local recurrence-free survival was 69% overall and 91% for abdominal wall tumors. Reported recurrence rates range from 24% to 77% for extremity tumors and 57–86% for intra-abdominal tumors in FAP, and 63% (103/163) of survey participants reported regrowth or recurrence after surgery.
- Desmoid tumors “typically have a limited impact on mortality” (SpringWorks Therapeutics). A Danish study reported a 5-year mortality rate of 7 per 1000 among patients with desmoid tumors and 5 per 1000 in a healthy matched cohort, with most deaths in patients with FAP. In a surgical series, 8 of 44 deaths were due to disease, all after R2 resection.
- Among 154 participants with intra-abdominal desmoid tumors, 5-year survival for stages I, II, III, and IV was 95%, 100%, 89%, and 76%, and 53% for stage IV patients with all identified risk factors; 5-year survival was 72% with home parenteral nutrition and 95% without it.
- Immunome's presentation states that approximately 50% of patients have desmoid tumors for more than 5 years, citing an ESMO Sarcoma 2024 poster.
Summary: symptoms and health-related quality of life
- Symptom presentation ranges from no symptoms to severe pain and functional limitation. Among 399 survey participants, signs and symptoms at diagnosis included an unexplained bump (60%), pain (57%), and fatigue (14%); tumor pain was documented in 57.4% of patients in the University of Utah Health network.
- Up to 63% of patients experience chronic pain, which leads to sleep disturbance in 73% of cases. In a cohort of 382 participants, the prevalence of pain was 36%, and pain at baseline was associated with poor quality of life, depression, and functional impairment.
- In concept elicitation interviews with 31 participants, fear (26 mentions), difficulty sleeping (24), anxiety (22), and depression (20) were frequently reported impacts; median disturbance ratings were 8.50 for hopelessness, 8.00 for depression, and 8.00 for financial difficulties.
- Among 235 participants in the United Kingdom and the Netherlands, 31% were in a high symptom burden cluster with clinically relevant lower HRQoL scores. In a study of 102 participants with desmoid tumors and 102 healthy controls, mean global health status was 65.58 among patients, and anxiety and depression were observed in 39.22% and 50% of patients. Anxiety and depression levels may be commensurate with those associated with malignant sarcomas.
- Survey participants with a current desmoid tumor reported significantly worse pain, fatigue, physical functioning, and sleep than those without one; among 322 respondents, 47% used NSAIDs and 19% used opioids for symptom management.
- In the NICE appraisal of nirogacestat, the DeFi trial did not collect EQ-5D data; the utility value for progressed disease was 0.263 in the company base case and 0.560 in the EAG base case, both drawn from soft-tissue sarcoma data.
Summary: economic, family, and diagnostic testing burden
- A systematic literature review identified no studies evaluating the direct or indirect costs of patients with desmoid tumors. Within 3 years after diagnosis in Danish registers, patients had on average 1 inpatient and 7.1 outpatient visits and 7.5 days in hospital, compared with 0.8, 0.1, and 0.8 in the matched comparison cohort; 70% of surgically treated and 63% of non-surgically treated patients used chemotherapeutic agents, tyrosine kinase inhibitors, NSAIDs, opioids, antidepressants, or steroids in the 3 years after diagnosis.
- In the University of Utah Health network, patients averaged 2.4 desmoid-related outpatient visits per year, the median number of outpatient visits was 7.2 per patient per year during symptomatic disease, and 20.3% required desmoid-related hospitalization.
- In studies summarized by a systematic review, 26% of patients stopped working and 10% worked part time because of pain. An NHS Scotland costing of 10-year active surveillance estimated combined imaging and clinic costs exceeding £6500 per patient.
- The burden is “disproportionately borne by women of childbearing and working age”. The NICE committee noted effects on careers, relationships, social lives, the ability to have a family, and carers' quality of life. Pregnancy was associated with an increased risk of events at 24 months (HR = 2.09) in one cohort, and among 177 pregnancies in 157 women, progression during pregnancy ranged from 9.5% to 68.7% by group and spontaneous regression occurred in 23.7%.
- A prior misdiagnosis was reported by 41% (162/399) of survey participants, and 46% (58/126) of those with a misdiagnosis and surgery had surgery before a definitive diagnosis. In the Utah cohort, 29.1% potentially had a misdiagnosis, and hospitalization in the year before diagnosis was 25.6% among them vs 2.6% among others. Misdiagnosis rates may reach 30–40% during an initial work-up.
- CTNNB1 testing was documented in 6.7% of patients in the Utah cohort, “potentially due to cost and reimbursement issues”, and requested in 15.5% of cases at a United Kingdom specialist center. In the French RRePS network, expected 12-month costs per patient (2013 euros) were €8,791 with centralized histological review and €8,904 without it.